Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,758 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07433400Recruiting
Long-term study of adults with Ph+ ALL who relapsed or didn't respond
This trial follows adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that has come back or hasn't gotten better with treatment. It aims to understand how people do over time and what factors affect their health.
Pierre-BéniteAges 18 years+ - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Miami Beach, FloridaAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Palo Alto, CaliforniaAges 1 year+ - NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT06375733RecruitingPhase 1/Phase 2
GFH009 plus zanubrutinib for relapsed large B-cell lymphoma
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
NanningAges 18 years+ - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT06561152RecruitingPhase 1/Phase 2
Tagraxofusp plus low-intensity chemo for CD123+ AML
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
Palo Alto, CaliforniaAges 18 years+ - NCT06397027RecruitingPhase 1
Ziftomenib, venetoclax, and azacitidine for pediatric leukemia
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Houston, TexasAges 2–21 - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06146257RecruitingPhase 1
Study of GLB-001 for Relapsed or Refractory AML or High-Risk MDS
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Duarte, CaliforniaAges 18 years+ - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT04050280RecruitingPhase 2
Testing an antibody drug for relapsed or hard-to-treat AML
This trial studies a drug called CLAG-GO (an antibody with chemotherapy drugs attached) in adults with AML that has come back or did not respond to treatment. It aims to improve outcomes for people whose leukemia is persistent, relapsed, or refractory.
Baltimore, MarylandAges 18 years+ - NCT03629171RecruitingPhase 2
Liposome-encapsulated daunorubicin-cytarabine and venetoclax for acute myeloid leukemia
This trial tests a combination of two chemotherapy drugs packaged in a special fat coating (liposome) plus a targeted pill called venetoclax for adults with acute myeloid leukemia (AML) that has come back, not responded, or is newly diagnosed. The goal is to see if this combination is safe and effective.
Houston, TexasAges 18 years+ - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,758 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.